DNA analysis is a complex, lengthy, and in some cases unreliable process. gMendel® is a medical technology start-up that aims to make a lasting positive impact on the analysis of genetic disorders: diagnosing genetic disorders faster and more cost-effectively. Together with Netcetera and the University of Copenhagen, they have developed the Phivea® platform, which makes genetic analysis safer, more reliable, and more affordable. By combining genomics, AI and blockchain, gMendel®Test provides a shorter, safer, and more economical path to accurate diagnosis and potential treatment, ensuring the highest security and patient data encryption.
Phivea® was created by bringing together genomics, artificial intelligence, and blockchain. DNA sequences from up to 96 different individuals are linked together using barcodes and scanned in the Oxford Nanopore Sequencer. To analyze these different gene sequences, Netcetera has developed the machine learning algorithm Torchlex. Torchlex reduces computational complexity and significantly increases the speed of analysis while maintaining the same quality and accuracy compared to competing methods. This method allows to significantly reduce the cost of analysis per gene sample.
The personal experiences of the two initiators and founders of gMendel®, Chris Kyriakidis and Zoran Velkoski, were decisive for the development of this method. Chris Kyriakidis' daughter was diagnosed with selective mutism. After making remarkable progress, she is now taking part in all learning and social activities at her school. Zoran Velkoski's school friend was diagnosed with a rare type of cancer that could only be determined by DNA sequencing. This technology has been available for a long time. However, it was unfortunately very expensive and therefore not affordable for many people. The two entrepreneurs set out to make DNA sequencing routine clinical practice by using smart technology to enable early, accurate and affordable diagnosis of genetic disorders. The aim is to transform the diagnosis of genetic disorders for better disease management.
We have a multinational team of experts in different locations and from different disciplines. Netcetera with artificial intelligence and machine learning, Star Global developing software as a medical device, collaborators responsible for the regulatory part, molecular biologists and researchers in the lab, and others. The holistic approach of these collaborators and working together has contributed to the creation of the Phivea® platform. Only through this close collaboration between partners it was possible to archive the ISO13485 certification from LRQA and release Phivea® just seven months after the project kickoff. The success gMendel has experienced would not be possible without Netcetera contribution.
Artificial Intelligence has already been used in medicine. Blockchain has a strong presence in other industries. The same is true for genomics, which is used in universities and hospitals. Our innovation is to connect the different disciplines and make them accessible and affordable for everyone. Currently, we offer this for genetic disorders, but in the future, we want to be able to diagnose more complicated disorders reliably, quickly, and economically.
From a technological point of view, it was very interesting to combine the different topics. The whole process from lab preparation to sequencing to diagnosis is a unique process that we are now doing as a whole.
On this topic